JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
September 3, 2019 9:00 AM EDT
Social media campaign designed to spark MPN conversations and increase awareness and education about MPNs, a group of rare, chronic blood cancers, launches today
To further support the MPN community, for every weekly challenge completed in September, Incyte will donate to The Leukemia & Lymphoma Society
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte (NASDAQ: INCY) is proud to further elevate awareness of myeloproliferative neoplasms (MPNs) throughout the month of September in honor of Blood Cancer Awareness Month and... More
September 3, 2019 8:14 AM EDT
Updated Phase 2 results from the FIGHT-202 study highlight the potential of pemigatinib as a treatment option for patients with previously treated, advanced cholangiocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte (Nasdaq: INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and... More
